Publications

  • Siegal T, Raz I, Polliack A. Nervous system involvement in malignant lymphoma. Harefuah 103(10):251-254,1982.
  • Raz I, Haas H. Tuberculous axillary lymphadenitis - an unusual presentation. Tubercle 64:41-42,1983.
  • Shaked A, Raz I, Gottehrer A, Romanoff H. Asymptomatic, highly vascularized superior mediastinal mass. Chest 86(4):621-622,1984.
  • Raz I, Gottlieb D, Bar-On H. Acute dysphasia associated with hypoglycemia. Is J Med Sc 20(8):729-730,1984.
  • Raz I, Katz M, Aram H, Haas H. Sporitrichoid Myobacterium marinum infection: Report of a ten year case. Int J Dermatol 23(8):554-555,1984.
  • Raz I, Or R, Okon E, Leizerwitz R, Polliack A. Hairy cell leukemia: report of an unusual case with hepatomegaly due to a large vascular tumor of the liver, mediastinal mass and pleural effusion containing hairy cells. Acta Haematol 71(6):393-399,1984.
  • Leitersdorf E, Israeli A, Raz I. Anorexia nervosa - an unusal presentation of the Plummer-Vinson syndrome. Int J Psych Med 14:343-346,1984.
  • Weiss AT, Flugelman MY, Lewis BS, Raz I, Halon DA, Gotsman M. Isolated right ventricular infarction with ventricular tachyarrhythmia. Am Heart J 108(2): 425-426, 1984.
  • Bialer M, Hussein Z, Dubrovsky J, Raz I, Abramsky O. Pharmacokinetics of valproic acid obtained after administration of three oral formulations to humans. Isr J Med Sci 20 (1): 46-49, 1984.
  • Raz I,  Polliack A. Coexistence of myelomonocytic leukemia and monoclonal gammopathy or myeloma. Simultaneous presentation in three patients. Cancer 53 (1): 83-85, 1984.
  • Raz I, Shinar E, Polliack A. Pancytopenia with hypercellular bone marrow. A possible paraneoplastic syndrome in carcinoma of the lung. A report of  three cases. Am J Hematol 16 (4): 403-408,1984.
  • Raz I,  Bar-On H,  Kidron M,  Ziv E. Rectal administration of insulin. Isr J Med Sci 20 (2):173-175,1984.
  • Raz I,  Bialer M,  Salame K,  Bar-On H. Comparative pharmacokinetic analysis of a novel sustained - release dosage from theophylline in humans. Eur J Clin Pharmacol 26 (3): 401-403, 1984.
  • Hass H, Katz M, Raz I Isolation of the new species, Mycobacterium fallax in Israel. Isr J Med Sci 20 (11):1097-1098,1984.
  • Raz I,  Siegal T,  Polliack A.  CNS involvement by non-Hodgkin's lymphoma: Response to a standard therapeutic protocol. Arch Neurol 41 (11): 1167-1171,1984.
  • Raz I, Koffler M, Leitersdorf E, Bar-On H. Maintenance of ambulatory diabetic patients on subcutaneous insulin pump. Isr J Med Sci 20 (8): 731-735, 1984.
  • Bialer M, Rubinstein A, Raz I, Abramsky O. Pharmacokinetics of valpromide after oral administration of a solution and a tablet to healthy volunteers. Eur J Clin Pharmacol 27 (4):501-503, 1984.
  • Bialer M, Salame K, Raz I Effect of sustained release on the pharmacokinetics of theophylline in healthy subjects. Int J Clin Pharmacol Ther Toxicol 23 (12): 662-667,1985.
  • Or R, Raz I, Polliack A. Hairly cell leukemia associated with carcinoma. Blut 50 (5): 299-301, 1985.
  • Bialer M, Hussein Z, Raz I, Abramsky O, Herishanu Y, Pachys F. Pharmacokinetics of valproic acid in volunteers after a single dose study. Biopharm Drug Dispos 6(1):33-42,1985.
  • Bialer M, Friedman M, Dubrovsky J, Raz I, Abramsky O.  Pharmacokinetic evaluation of novel sustained-release dosage forms of valproic acid in humans. Biopharm Drug Dispos 6 (4): 401-411,1985.
  • Raz I, Fisher S, Israeli A, Gottehrer N, Chisin R, Kleinman Y. An unusual case of rheumatic pneumonia. Arch Int Med 145(6):1130-1131,1985.
  • Rubinstein A, Bialer M, Frieman M, Raz I, Abramsky O. A combined approach to control   valproic acid - a kinetic and pharmacokinetic study. J Control Release 4:33-38,1986.
  • Hussein Z, Bialer M, Friedman M, Raz I. Pharmacokinetic analysis of sustained-release dosage forms of theophylline in humans: comparison of single and multiple dose studies. Biopharm. Drug Dispos 8 (5): 427-435, 1987.
  • Micaeli J, Lugassy G, Raz I, Uzieli B, Polliack A. Chronic lymphocytic leukemia and malignant lymphoma developing in patients with autoimmunity or other ill -defined immune stigmata: a review of the literature and report of an additional 9 cases. Hematol Rev 1: 291-310, 1987.
  • Raz I, Leitersdorf E, KleinmanY. Acute bilateral brachial plexus neuritis associated with hypersensitivity vasculitis. A case report and review of the literature. Klin Wochenschr 63(14): 643-645,1985.
  • Or R, Raz I, Rave D, Lichovitzki G, KleinmanY. Thymoma presenting as a superior vena cava syndrome remission following therapy. Klin Wochenschr 65(13): 617-619,1987.
  • Caraco Y, Rave D, Raz I. Shigella sonnei myocarditis. Clin Cardiol 10(7): 423-424, 1987.
  • Raz I. Hyperglycemia – its relation to diabetic neuropathy. Harefuah 112: 22-25, 1987 (Hebrew).
  • Raz I. Diabetic nephropathy. Treatment with low protein diet. Harefuah 113 (3, 4): 75-77,1987 (Hebrew).
  • Haas H, Raz I, Katz S. Tuberculous cervical lymphadenitis. Harefuah 112: 297-299,1987 (Hebrew).
  • Arnon R, Raz I, Chajek-Shaul T, Berkman N, Field S, Bar-On H. Amiodarone pulmonary toxicity presenting as a solitary lung mass. Chest 93(2):425-427, 1988.
  • Raz I, Soskolne V, Stein P.  Inluence of small group education sessions on glucose hemostasis in NIDDM.  Diabetes Care 11 (1): 67- 71, 1988.
  • Raz I, Havivi E. Influence of chronic diabetes on tissue and blood cells status of zinc, copper and chromium in the rat. Diabetes Res 7 (1): 19-23, 1988.
  • Raz I, Ben David J, Hussein Z, Samara E. Comparative phamacokinetic analysis of novel sustained-release dosage forms of pentoxifulline in healthy subjects. Int J Clin Pharmacol Ther Toxicol 26 (4): 206-208, 1988.
  • Raz I, Hussein Z, Samara E, Ben-David J. Comparative pharmacokinetic analysis of a novel sustained-release dosage form of diclofenac sodium in healthy subjects. Int J Clin. Pharmacol. Ther. Toxicol 26 (5): 246-248, 1988.
  • Raz I,  Rosenblit H,  Kark JD. Effect of moderate exercise on serum lipids in young men with low high density lipoprotein cholesterol. Arteriosclerosis 8 (3): 245-251, 1988.
  • Raz I,  Hasdai D,  Seltzer Z,  Melmed RN. Effect of hyperglycemia on pain perception and on efficacy of morphine analgesia in rats. Diabetes 37 (9): 1253-1259, 1988.
  • Raz I,  Adler JH,  Havivi E. Altered tissue content of trace metals in diabetic hyperinsulinaemic sand rats (Psammomys obesus). Diabetologia 31 (5): 329-333, 1988.
  • Raz I, Havivi Y, Yarom R. Reduced negative surface charges on arterial endothelium of diabetic rats. Diabetologia 31 (8): 618-620, 1988.
  • Raz I, Israeli A,  Rosenblit H,  Bar-On H. Influence of moderate exercise on glucose homeostatsis and serum testosterone in young men with low HDL-cholesterol level. Diabetes Res 9 (1): 31-35,1988.
  • Caraco Y, Arnon R, Raz I. Atrioventricular block complicating acute streptococcal tonsilitis. Br Heart J 59(3): 389-390,1988.
  • Caraco Y, Raveh D, Flugelman M, Raz I. Enhanced anticoagulation effect of acenocoumarol induced by amyodarone coadministration. Isr J Med Sci 24: 688-689, 1988.
  • Israeli A, Matzner Y, Or R, Raz I. Gibenclamida causing thrombocytopenia and bleeding tendency: case reports and review of the literature. Klin Wochenschr 66(5): 223-224,1988.
  • Raz I, Okon E, Chajek-Shaul T. Pulmonary manifestations in Behcet’s syndrome. Chest 95 (3): 585 - 589,1989 (Review).
  • Raz I, Havivi E. Trace elements in blood cells of diabetic subjects. Diabetic Res 10 (1): 21-24,  1989.
  • Raz I, Karsai D, Katz M. The influence of zinc supplementation on glucose homeostasis in NIDDM. Diabetes Res 11 (2): 73-79,1989.
  • Zusman I, Yaffe P, Raz I, Bar-On H, Ornoy A. Effects of human diabetic serum on the in vitro development of early somite rat embryos. Teratology 39 (1): 85-92,1989.
  • Kidron M, Krausz M, Raz I, Baron H, Ziv E. The absorption of insulin from dog                                                                 intestine is facilitated by bile acids. Tenside Surf Det 26: 352-354, 1989.
  • Kennington AS, Hill CR, Craig J, Bogardus C, Raz I, Ortmeyer HK, Hansen BC, Romero G, Larner J. Low urinary chiro-inositol excretion in non-insulin-dependent diabetes mellitus. New Engl J Med 323 (6): 373-378,1990.
  • Zurlo F, Lillioja S, Esposito-Del-Puente A, Nyomba BL, Raz I, Saad MF, Swinburn BA, Knowler WC, Bogardus C, Ravussin E. Low ratio of fat to cardohydrate oxidation as predictor of weight gain – study of 24-h RQ. Am J Physiol 259 (5 Pt 1): E650-657,1990.
  • Harats D, Manny H, Raz I. Autoimmune hemolytic anemic in Gaucher’s disease. Klin Wochenschr 68(2):94-95,1990.
  • Caraco Y, Arnon R, Raz I. Bethanechol induced cholinergic toxicity in diabetic neuropathy. DICP 24(3):327-328,1990.
  • Harats D, Raz I, Lebensart P. Ultrasonographic appearance of well defined splenic       space-occupying lesions in Gaucher’s disease. Isr J Med Sci 26(3):168-170,1990.
  • Nyomba BL, Freymond D, Raz I, Stone K, Mott DM, Bogardus C. Skeletal muscle glycogen synthase activity in subjects with non-insulin dependent diabetes mellitus after glyburide therapy. Metabolism 39 (11):1204-1210,1990.
  • Raz I,  Katz A, Spencer K. Ephinephrine inhibits insulin-mediated glycogenesis but enhances glycolysis in human skeletal muscle. Am J Physiol 260 (3 pt 1):E430-435,1991.
  • Spencer MK, Katz I, Raz I. Ephinephrine increases tricarboxylic acid cycle intermediates  in human skeletal muscle. Am J Physiol 260 (3 pt 1): E436-439,1991.
  • Katz A, Raz I, Spencer M K, Rising R, Mott MD. Hyperglycemia induces accumulation of glucose in human skeletal muscle. Am J Physiol 260 (4 pt 2): R698-703,1991.
  • Maeda R, Raz I,  Zurlo F, Sommercorn J. Activation of skeletal muscle casein kinase II by insulin is not diminished in subjects with insulin resistance. J Clin Invest 87(3):1017-1022, 1991.
  • McGuire MC, Fields RN, Nyomba B L, Raz I, Bogardous C, Tonks NK, Sommercorn J. Abnormal regulation of protein tyrosine phsophatase activities in skeletal  muscle of insulin-resistant humans. Diabetes 40(7):939-942,1991.
  • Swinburn BA, Nyomba BL, Saad MF, Zurlo F, Raz I, Knowler WC, Lillioja S, Bogardus C, Ravussin E. Insulin resistance associated with  lower rates of weight gain in  Pima Indians. J. Clin Invest 88(1):168-173,1991.
  • Havivi E, Bar On H, Reshef A, Stein P, Raz I. Vitamins and trace metals status in non insulin dependent diabetes mellitus. Int J Vit Nutr Res 61(4):328-333,1991.
  • Kida Y, Raz I, Maeda R, Nyomba B L, Stone K, Bogardus C, Sommercorn J, Mott DM. Defective insulin response of phosphorylase phosphatase in insulin-resistant humans. J Clin Invest 89 (2):610-617,1992.
  • Raz I, Levinger S, Maravi Y, Sigelmann N, Shananas M, Bursztyn M. Prevalence of glucose intolerance in young male Ethiopian immigrants. Isr J Med Sci 29 (6-7):347-350,1993.   
  • Bursztyn M, Raz I. Blood pressure, glucose, insulin and lipids of young Ethiopian recent immigrants to Israel and in those residents for 2 years. J Hyperten 11 (4):455-459,1993.
  • Raz I, Chigier E, Rosenblit H, Mevorach R, Bursztyn M. Comparison of glucose tolerance, lipids and blood pressure in young male Ethiopeans from two different immigrations – 1989 and 1991. Isr J Med Sci 29 (6-7): 351-354,1993.
  • Bursztyn M, Ben-Ishay D, Shochina M, Mekler J, Raz I. Disparate effects of exercise training on glucose tolerance and insulin levels and on ambulatory blood pressure in hypertensive patients.J Hypertens 11(10):1121-1125,1993.
  • Bursztyn M, Ben-Ishay D, Mekler J, Raz I. Chronic exogenous hyperinsulinemia without sugar supplementation: acute salt-sensitive hypertension without changes in resting blood pressure. J Hypertens 11(7): 703-707,1993.
  • Sommercorn J, Fields R, Raz I, Maeda R. Abnormal regulation of ribosomal protein S6 kinase by insulin in skeletal muscle of insulin- resistant humans. J Clin Invest 91 (2):509-513, 1993.
  • Bursztyn M, Raz I, Mekler J, Ben-Ishay D. Nitrendipine improves glucose tolerance and deoxyglucose uptake in hypertensive rats. Hypertension 23 (6 pt 2): 1051-1053,1994.
  • Raz I, Hauser E, Bursztyn M.  Moderate exercise improves glucose metabolism in uncontrolled elderly patients with non-insulin-dependent diabetes mellitus. Isr J Med Sci 30 (10):766-770,1994.
  • Bialer M,  Phara JZ,  Zuckerman S,  Raz I,  Abramsky O, Sterling J,  Ladkani D. Pharmacokinetic analysis of valdice dielhylcarbonate product of acid. Eur J Pharm Sci 2: 239-244,1994.
  • Katz A,  Raz I.  Hexokinase kinetics in human skeletal muscle after hyperinsulinaemia, hyperglycemia and hyperepinephrinaemia. Acta Physio Scand 151 (4):527-530,1994.
  • Raz I, Gilhar D, Hoffman A. Prolonged response to Glibenclamide in NIDDM patients in a normoglycemic state. Isr J Med Sci 30 (10):775-778,1994.
  • Hoffman A, Fischer Y, Gilhar D, Raz I. The effect of hyperglycemia on the absorption of glibenclamide in patients with non-insulin dependent diabetes mellitus. Eur J Clin Pharmacol 47 (1):53-55,1994.
  • Raz I. Exocrine insufficiency in transplanted pancreas imitating pancreatic rejection. Diabetes Care 17(7): 779-780,1994.
  • Bursztyn M, Raz I, Ben-Ishay D. Blood pressure measurement method not responsible for results of Brands et al (Letter). Am J Hypertens 7(11):1033, 1994.
  • Katz A, Raz I.  Rapid activation of glycogen synthase and protein phosphatase in human skeletal muscle after isometric contraction requires an intact circulation. Pflugers Arch 431(2):259-265,1995
  • Bursztyn M, Raz I. Prediction of hypertension by the insulinogenic index in young Ethiopian immigrants. J Hypertens 13(1):57-61,1995.
  • Philip M, Landau D, Segev Y, Weiss O, Raz I. Insulin-like growth factors (IGFs) and IGF-binding protein in diabetic kidney disease. Isr J Med Sci 31(12):712-716,1995.
  • Weiss O, Anner H,  Nephesh I, Alayoff A, Bursztyn M,  Raz I. Insulin-like growth factor-I (IGF-I ) and IGF-I receptor gene expression in the kidney of the chronically hypoinsulinemic rat and hyperinsulinemic rat. Metabolism 44(8):982-986,1995.
  • Friedlander M, Popovtzer MM, Weiss O, Nefesh I, Kopolovic J, Raz I. Insulin-like growth factor -1 (IGF-1)enhances recovery from HgC12-induced acute renal failure: the effects on renal IGF- 1, IGF -1 receptor and IGF-binding protein-1 mRNA. J Am Soc Nephrol 5 (10): 1782-1791,1995.
  • Bursztyn M, Raz I. Blood pressure and insulin in Ethiopian immigrants: Longitudinal study. J Hum Hypertens 9 (4): 245-248, 1995.
  • Meirow D, Yossepowitch O, Rosler A, Brezezinski A, Schenker JG, Laufer N, Raz I.  Insulin resistant and non-resistant polycistic ovary syndromes represent two distinct clinical and endocrinological subgroups. Hum Reprod 10 (8):1951-1956, 1995.
  • Bursztyn M, Ben-Ishay D, Mekler J, Raz I. Chronic exogenous hyperinsulinemia accelerates the development of hypertension in spontaneously hypertensive rats. Clin Exp Pharmacol Physiol Suppl 22 (1): S28-29,1995.
  • Bursztyn M, Ben-Ishay D, Mekler J, Raz I. Insulin induced renal dysfunction in regular Sabra rats. Clin Exp Pharmacol Physiol Suppl 22 (1): S32-33, 1995.
  • Ornoy A, Zaken V, Abir R, Yaffe P, Raz I. Effects on rat embryos of culture in serum of women with gestational diabetes. Toxic in Vitro 9: 643-651, 1996.
  • Ornoy A, Kimyagarov D, Yaffee P, Abir R, Raz I, Kohen R. Role of reactive oxygen species in diabetes induced embryotoxicity: studies on pre-implantation mouse embryos cultured in serum from diabetic pregnant women. Isr J Med Sci 32(11): 1066-1073, 1996.
  • Leibowitz G, Tsur A, Chayen SD, Salameh M, Raz I, Cerasi E, Gross DJ. Pre-clinical Cushing’s syndrome: an unexpected frequent cause of poor glycaemic control in obese diabetic patients. Clin Endocrino Oxf 44 (6): 717 - 722, 1996.
  • Meirow D, Raz I, Yossepowitch O, Brzezinski A, Rosler A, Schenker JG, Berry EM. Dyslipidemia in polycystic ovarian syndrome: different groups, different etiologies? Hum Reprod 11(9):1848-1853, 1996.
  • Cohen SE, Raz I, Safadi R. A patient with hypoparathyroidism, dysmorphic features and mental retardation. Eur J Med Res 1(5): 266-268,1996. (Review)
  • Schulz-Knappe SE, Raz I, Safadi R. A patient with hypoparathyroidism, dysmorphic features and mental retardation. Eur. J Med Res 1: 266-268, 1996.
  • Bursztyn M, Raz I, Mekler J, Ben-Ishay D. Effect of acute N-nitro-L-arginine methyl ester (L- NAME) hypertension on glucose tolerance, insulin levels and [3H] deoxyglucose muscle uptake. Am J Hypertens 10(6):683-686, 1997.
  • Raz I,  Rubinger D,  Popovtzer M,  Gronback H,  Weiss O, Flyvbjerg A. Octreotide prevents the early increase in renal insulin-like growth factor binding protein 1 in streptozotoc in diabetic rats. Diabetes  47(6):924-930,1998. Erratum in Diabetes 47(7): 1170, 1998.
  • Rubinger D, Weiss O, Zarfati D, Popovtzer MM, Raz I. The effect of low dose octreotide administration on renal function and on gene expression of IGF-I axis components in experimental diabetes mellitus. J Endocrinol 159(1): 133-140, 1998.
  • Mosseri M, Nahir M, Rozenman Y, Lotan C, Admon D, Raz I, Gotsman MS. Diffuse narrowing of coronary arteries in diabetic patients: the earliest phase of coronary artery disease. Cardiology 89 (2): 103-110, 1998.
  • Averbukh E, Weiss O, Halpert M, Yanko R, Moshe R, Nephesh I, Flyvbjerg  A,  Yanko L, Raz I. Gene expression of insulin-like growth factor-I, its receptor and binding proteins in retina under hypoxic conditions. Metabolism 47 (11): 1331-1336, 1998.
  • Symon Z,  Fuchs S,  Agmon Y, Weiss O, Nephesh I, Moshe R, Brezis M, Flyvbjerg, A,  Raz I. The endogenous insulin-like growth factor system in radiocontrast nephropathy. Am J Physiol 274 (3 Pt 2): F490-497, 1998.
  • Cohen Y, Raz I,  Merin G,  Mozes B.Comparison of factors associated with 30 day mortality after coronary artery bypass grafting in patients with versus without diabetis mellitus. Israeli Coronary Artery Bypass (ISCAB) Study Consortium. Am. J. Cardiol 81 (1): 7-11, 1998.
  • Hirshberg B, Trelezky V, Raz I. Hypoglycaemia following pancreatic allograft transplantation.  J Int Med 243 (5):389-393, 1998.
  • Lomnicky Y, Friedman M, Luria MY, Raz I, Hoffman A. The effect of the mode of administration on the hypolipidaemic activity of Niacin: Continuous gastrointestinal administration of low-dose niacin improves lipid-lowering efficacy in experimentally-induced hyperlipidaemic rats. J Pharm. Pharmacol 50 (11): 1233-1239, 1998.
  • Mumcuoglu KY, Ingber A, Gilead L, Stessman J, Friedmann R, Schulman H, Bichucher H, Ioffe-Uspensky I, Miller J, Galun R, Raz I. Maggot therapy for the treatment of diabetic foot ulcers (Letter) Diabetes Care 21:2030-2031, 1998.
  • Freier S, Weiss O, Eran M, Flyvbjerg A, Dahan R, Nephesh I, Safra T, Shiloni E, Raz I. Expression of the insulin-like growth factors and their receptors in adenocarcinoma of the colon. Gut 44 (5):704-8, 1999.
  • Abulafia-Lapid R, Elias D, Raz I, Keren-Zur Y, Atlan H, Cohen IR. T cell proliferative responses of type 1 diabetes patients and healthy individuals to human hsp60 and its peptides. J Autoimmun 12 (2):121-129, 1999.
  • Mumcuoglu KY, Ingber A, Gilad L, Stessman J, Friedman R, Schulman H, Bichucher H, Ioffe-Uspensky I, Miller J, Galun R, Raz I. Maggot therapy for the treatment of intractable wounds. Int J Dermatol 38(8):623-627, 1999.
  • Datta U, Wexler ID, Kerr DS, Raz I, Patel MS. Characterization of the regulatory region of the human testis-specific form of the pyruvate dehydrogenase alpha-subunit (PDHA-2) gene. Biochim Biophys Acta 1447 (2-3):236-43, 1999.
  • Sade K, Schwartz D, Wolman Y, Schwartz I, Chernichovski T, Blum M, Brazowski E, Keynan S, Raz I, Blantz RC, Iaina A. Time course of lipopolysaccharide-induced nitric oxide synthase mRNA expression in rat glumeruli. J Lab Clin Med 134(5): 471-7, 1999.
  • Stern E, Raz I, Weitzman S. Prevalence of diabetes mellitus among workers in Israel: a nation-wide study. Acta Diabetol 36(4): 169-72, 1999.
  • Keynan S, Hirshberg B, Levine-Iaina N, Wexler ID, Dahan R, Reinhartz E, Ovadia, H., Wollman Y, Chernihovskey T, Iaina A, Raz I. Renal nitric oxide production during the early phase of experimental diabetes mellitus. Kidney Int 58 (2): 740-7, 2000.
  • Shpichinetsky V, Raz I, Friedlander Y, Goldschmidt N, Wexler ID, Ben-Yehuda A, Friedman G. The association between two common mutations C677T and A1298C in human methylenetetrahydrofolate reductase gene and the risk for diabetic nephropathy in type II diabetic patients. J Nutr 130 (10): 2493-7, 2000.
  • Raz I, Wexler ID. Biomedical research in Israel: does it have a future? Isr Medical Assoc J 2 (7): 495-8, 2000.
  • Averbukh E, Halpert M, Yanko R, Yanko L, Peer J, Levinger S, Flyvbjergh A, Raz I. Octreotide a somatostatin analogue fails to inhibit hypoxia-induced retinal neovascularisation in the neonatal rat. Int J Exp Diabetes Res 1 (1):39-47, 2000.
  • Stepensky D, Friedman M, Srour W, Raz I, Hoffman A. Preclinical evaluation of pharmacokinetic – pharmacodynamic rationale for oral CR metformin formulation. J Control Release 71 (1):107-15, 2001.
  • Bursztyn M, Flyvbjerg A, Weiss O, Mekler J, Raz I. Atrophy or hypertrophy in chronic renal ischemia: roll of the IGF-I system. Am J Hypertens 14 (12): 1211-1218, 2001.
  • Raz I, Elias D, Avron A, Tamir M, Metzger M, Cohen IR. Beta–cell function in new- onset type 1 diabetes by specific immunomodulation with heat shock protein peptide (Diapep 277): a randomized, double-b phase II trial. Lancet 358 (9295):1749-53, 2001.
  • Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Polh M, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I. Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Eng J Med 345(12):851-860, 2001.
  • Wainstein J, Metzger M, Wexler ID, Cohen J, Raz I. The use of continuous insulin delivery systems in severely insulin-resistant patients. Diabetes Care 24 (7):1299, 2001.
  • Raz I. Editor's Foreword. Diabetes Obes Metab 3 suppl 1:1-2, 2001.
  • Wainstein J, Metzger M, Minuchin O, Harmann I, Cohen Y, Jaffe A, Raz I. Pump treatment for severely insulin resistant diabetic patients (Letter). Diabetes Care 24: 7 1299, 2001.
  • Metzger M, Leibowitz G, Wainstein J, Glaser B, Raz I. Reproducibility of glucose measurements using the glucose sensor. Diabetes Care 25 (7): 1185-91, 2002.
  • Khamaisi M, Flyvbjerg A, Haramati Z, Raz G, Wexler ID, Raz I. Effect of mild hypoinsulinemia on renal hypertrophy: growth hormone/insulin –like growth factor I system in mild streptozotocin diabetes. Int J Exp Diabetes Res 3 (4):257-64, 2002.
  • Tepensky D, Friedman M, Raz I, Hoffman A. Pharmacokinetic-pharmacodynamic analysis of the glucose-lowering effect of metformin in diabetic rats reveals first-pass pharmacodynamic effect. Drug Metab Dispos 30(8):861-8, 2002.
  • Khamaisi M, Raz I. Diabetes epidemic and the thrifty gene. Isr Med Assoc J 4 (9):720-721, 2002.
  • Raz I, Wexler I, Weiss O, Flyvbjerg A, Segev Y, Rauchwerger A, Raz G, Khamaisi M. Role of insulin and the IGF system in renal hypertrophy in diabetic Psammomys obesus (sand rat).Nephrol Dial Transplant 18 (7):1293-8, 2003.
  • Khamaisi M, Schrijvers BF, De Vriese AS, Raz I, Flyvbjerg A. The emerging role of VEGF in diabetic kidney disease. Nephrol Dial Transplant 18 (8):1427-30, 2003.
  • Raz I, Rosengarten Y, Carasso R. Correlation study between conventional medical diagnosis and the diagnosis by reflexology (non-conventional). Harefuah 143(8-9):600-605, 646, 2003. (Hebrew)
  • Berl T, Hunsicker LG, Lewis JB, Pfeffer MA, Porush JG, Rouleau JL, Drury Pl, Esmatjes E, Hricik D, Parikh CR, Raz I, Vanhille P, Wiegmann TB, Wolfe BM, Locatelli F, Goldhaber SZ, Lewis EJ; Irbesartan Diabetic Nephropathy Trial. Collaborative Study Group.  Cardiovascular Outcomes in the Irbesartan Diabetic Nephropathy Trial (IDNT) of Patients with Type 2 diabetes and overt nephropathy.  Ann Inter Med 138 (7):542-549, 2003 [Summary for patients in Ann Inter Med. 138(7):143, 2003]
  • Roth A, Kalter-Leibovici O, Kerbis Y, Tenenbaum-Koren E, Chen J, Sobol T, Raz I. Prevalence and risk factors for erectile dysfunction in men with diabetes, hypertension, or both diseases: a community survey among 1,412 Israeli men. Clin Cardiol 26 (1):25-30, 2003.
  • Khamaisi M, Wainstein J, Hancu N, Milicevic Z, Raz I. Association of hyperglycemia and insulin with diabetic cardiovascular complications. Isr Med Assoc J 5 (2):116-9, 2003.
  • Shafrir E, Raz I. Diabetes: mellitus or lipidus? Diabetologia 46 (3):433-40, 2003.
  • Shafrir E, Raz I. Diabetes: mellitus or lipidus? Author's reply. Diabetologia 46 (11):1587, 2003.
  • Gronbaek H, Tanos V, Meirow D, Peretz T, Raz I, Flyvbjerg A. Effects of tamoxifen on insulin –like growth factors, IGF binding proteins and IGFBP-3 proteolysis in breast cancer patients. Anticancer Res May- Jun 23 (3C):2815-20, 2003.
  • Bursztyn M, Podjarny E, Dahan R, Raz I, Bernheim J. Insulin-induced hypertension, L-arginine, and endothelial nitric oxide synthase in pregnant rats. Hypertens Pregnancy 22 (3):267-74, 2003.
  • Khamaisi M, Wexler ID, Shrha J, Strojek K, Raz I, Milicevic Z. Cardiovascular disease in type 2 diabetics: epidemiology, risk factors and therapeutic modalities. Isr Med Assoc J 5 (11):801-6, 2003.
  • Milicevic Z, Raz I. Interventions in diabetic patients after myocardial infarction. Acta Diabetol. 40 Suppl 2:S348-53, 2003.
  • Cernea S, Hancu N, Raz I. Diet and coronary heart disease in diabetes. Acta Diabetol, 40 suppl 2:S389-400, 2003.
  • Raz I, Mouritzen U, Vaz J, Hershkovitz T, Wainstein J, Boehm I. Addition of biphasic insulin aspart 30 to rosiglitaxone in type 2 diabetes mellitus that is poorly controlled with glibenclamide monotherapy. Clin Ther 25 (12):3109-23, 2003.
  • Elazary AS, Lador N, Shauer A, Meir K, Pollak A, Wolf DG, Raz I, Leitersdorf E, Mevorach, D. Tongue necrosis and pericarditis. Lancet 363 (9413):948, 2004.
  • Keynan S, Khamaisi M, Dahan R, Barnes K, Jackson CD, Turner AJ, Raz I. Increased expression of endothelin-converting enzyme- 1c isoform in response to high glucose levels in endothelial cells. J Vasc Res 41(2):131-40, 2004.
  • Abdul-Ghani MA, Sabah M, Minuchin O, Vardi P, Raz I, Wainstein J. Primary prevention of type 2 diabetes: how do we do it? Isr Med Asso J. 6 (5):305-7, 2004.
  • Tsur A, Harman-Boehm I, Wainstein J, Raz I. Primary care for type 2 diabetes: Harefuah 143(5); 353-354, 2004. (Hebrew)
  • Anis Y, Leshem O, Reuveni H, Wexler I, Ben Sasson R, Yahalom B, Laster M, Raz I, Ben- Sasson S, Shafir E, Ziv E. Antidiabetic effect of novel modulating peptides of G-protein-coupled kinase in experimental models of diabetes. Diabetologia 47(7):1232-1244, 2004.
  • Anavekar NS, Gans DJ, Berl T, Rohde RD, Cooper W, Bhaumik A, Hunsicker LG, Rouleau JL, Lewis JB, Rosendorff C, Porush JG, Drury PL, Esmatjes E, Raz I, Vanhille P, Locatelli F, Goldhaber S, Lewish EJ, Pfeffer MA. Predictors of cardiovascular events in patients with type 2 diabetic nephropathy and hypertension: a case for albuminuria. Kidney Int Suppl 92:S50-55, 2004. Review
  • Eldor R, Raz I, Ben Yehuda A, Boulton AJ. New and experimental approaches to treatment of diabetic foot ulcers: a comprehensive review of emerging treatment strategies. Diabet Med 21(11):1161-1173, 2004. Review.
  • Raslova K, Boboev M, Raz I, Leth G, Gall MA, Hancu N. Insulin detemir and insulin aspart: a promising basal-bolus regimen for type 2 diabetes. Diabetes Res Clin Pract 666(2):193-201, 2004.
  • Cernea S, Kidron M, Wohlgelernter J, Modi P, Raz I. Comparison of pharmacokinetic and pharmacodynamic properties of single-dose oral insulin spray and subcutaneous insulin injection in healthy subjects using the euglycemic clamp technique. Clin Ther 26(12): 2084-2091, 2004.
  • Raz I, Eldor R, Cernea S, Shafrir E. Diabetes: insulin resistance and derangements in lipid metabolism. Cure through intervention in fat transport and storage. Diabetes Metab Res Rev 21(1):3-14, 2005. Review.
  • Fujioka K, Brazg RL, Raz I, Bruce S, Joyal S, Swanink R, Pans M. Efficacy, dose-response relationship and safety of once-daily extended-release metformin (Glucophage XR) in type 2 diabetic patients with inadequate glycaemic control despite prior treatment wit diet and exercise: results from two double-blind, placebo-=controlled studies. Diabetes Obes Metab 7(1):28-39, 2005
  • Raz I, Eldor R, Naparstek Y. Immune modulation for prevention of type 1 diabetes mellitus. Trends Biotechnol 23(3):128-134, 2005. Review.
  • Milicevic Z, Raz I, Strojek K, Skrha J, Tan MH, Wyatt JW, Beattie SD, Robbins DC; HEART2D Study. Hyperglycemia and its effect after acute myocardial infarction of cardiovascular outcomes in patients with Type 2 diabetes mellitus (HEART2D) Study design. J Diabetes Complications 19(2):80-87, 2005.
  • Abdul-Ghani MA, Sabbah M, Muati B, Dakwar N Kashkosh H, Minuchin O, Vardi P, Raz I. High frequency of pre-diabetes, undiagnosed diabetes and metabolic syndrome among overweight Arabs in Israel. Isr Med Assoc J 7(3):143-147, 2005.
  • Eldor R, Raz I. Lipids and glucose in type 2 diabetes: What about the beta-cell and the mitochondria? Response to Boden and Laakso. Diabetes Care 28(4):985-986, 2005. (Author reply, 986-987).
  • Yagil C, Barak A, Ben-Dor D, Rosenmann E, Bernheim J, Rosner M, Segev Y, Weksler-Zangen S, Raz I, Yagil Y. Nonproteinuric diabetes-associated nephropathy in the Cohen rat model of type 2 diabetes. Diabetes 54(5):P1487-1496, 2005.
  • Cernea S, Kidron M, Wohlgelernter J, Modi P, Raz I. Dose-response relationship of oral insulin spray in healthy subjects. Diabetes Care 28(6):1353-1357, 2005.
  • Berl T, Hunsicker LG, Lewis JB, Pfeffer MA, Porush JG, Rouleau JL, Drury PL, Esmatjes E, Hricik D, Pohl M, Raz I, Vanhille P, Wiegmann TB, Wolfe BM, Locatelli F, Goldhaber SZ, Lewis EJ. Impact of achieved blood pressure on cardiovascular outcomes in the irbesartan diabetic nephropathy trial. J Am Soc Nephrol 16(7):2170-2179, 2005.
  • Hillel J, Gefel D, Kalman R, Ben-Ari G, David L, Orion O, Feldman MW, Bar-On H, Blum S, Raz I, Schaap T, Shpirer I, Lavi U, Shafrir E, Ziv E. Evidence for a major gene affecting the transition from normoglycaemia to hyperglycaemia in Psammomys obesus. Heredity 95(2):158-165, 2005.
  • Eldor R, Stern E, Milicevic A, Raz I. Early use of insulin in type 2 diabetes. Diabetes Res Clin Pract Suppl 1:S30-35, 2005.
  • Kalter-Leibovici O, Wainstein J, Ziv A, Harman-Boehm I, Murad H, Raz I; Israel Diabetes Research Group (IDRG) Investigators. Clinical, socioeconomic and lifestyle parameters associated with erectile dysfunction among diabetic men. Diabetes Care 28(7):1739-1744, 2005.
  • Raz I. Complex impact of obesity on type 2 diabetes. Isr Med Assoc J 7(6):402-403, 2005.
  • Raz I. Peace building through health in Israel and Palestine. Lancet 366(9479):26. Letter, 2005.
  • Wainstein J, Metzger M, Boaz M, Minuchin O, Cohen Y, Yaffe A, Yerushalmy Y, Raz I, Harman-Boehm I. Insulin pump therapy vs. multiple daily injections in obese type 2 diabetic patients. Diabet Med 22(8):1037-1046, 2005.
  • Raz I, Stranks S, Filipczak R, Joshi P, Lertoft B, Rastam J, Chow CC, Shaban J. Efficacy and safety of biphasic insulin aspart 30 combined with pioglitazone in type 2 diabetes poorly controlled on glibenclamide (glyburide) monotherapy or combination therapy: an 18-week, randomized, open-label study. Clin Ther 27(9):1432-43, 2005.
  • Eldor R, Cohen IR, Raz I. Innovative immune-based therapeutic approaches for the treatment of type 1 diabetes mellitus. Int Rev Immunol 24(5-6): 327-39, 2005.
  • Cernea S. Kidron M, Wohlgelernter J, Raz I. Dose-response relationship of an oral insulin spray in six patients with type 1 diabetes: a single-center, randomized, single-blind, 5-way crossover study. Clin Ther 27(10):1562-70, 2005.
  • Khamaisi M, Keynan S, Bursztyn M, Dahan R, Reinhartz E, Ovadia H, Raz I. Role of renal nitric oxide synthase in diabetic kidney disease during the chronic phase of diabetes. Nephron Physiol 102(3-4):72-80, 2006.
  • Abdul-Ghani MA, Sabbah M, Kher J, Minuchin O, Vardi P, Raz I. Different contributions of insulin resistance and beta-cell dysfunction in overweight Israeli Arabs with IFG and IGT. Diabetes Metab Res Rev 22(2):126-30, 2006.
  • Knobler H, Benderly M, Boyko V, Behar S, Matas Z, Rubinstein A, Raz I, Wainstein J. Adiponectin and the development of diabetes in patients with coronary artery disease and impaired fasting glucose. Eur J Endocrinol 154(1):87-92, 2006. 
  • Cernea S, Raz I. Noninjectable methods of insulin administration.  Drugs of Today 42(6):405-424, 2006
  • Szalat A, Raz I. Metabolic syndrome and microangiopathy. Isr Med Assoc J 8(6):424-425, 2006
  • Weiss R, Raz I. Focus on childhood fitness, not just fatness. Lancet 368(9532):261-262, 2006.
  • Raz I: Introduction. Diabets Res Clin Pract 74 Suppl 1:S1-2, Epub 2006
  • Eldor R, Raz I: Lipotoxicity versus adipotoxicity-The deleterious effects of adipose tissue on beta cells in the pathogenesis of type 2 diabetes. Diabetes Res Clin Pract 74 Suppl 1:S3-8. Epub 2006
  • Tsur A, Harman-Boehm I, Buchs AE, Raz I, Wainstein J: The guidelines for the diagnosis, prevention and treatment of type 2 diabetes mellitus – 2005. Harefuah 145(8):583-6, 630, 2006 (Hebrew)
  • Ziegler D, Ametov A, Barinov A Dyck PJ, Gurieva I, Low PA, Munzel U, Yakhno N, Raz I, Novosadova M, Maus J. Samigullin R: Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial. Diabetes Care 29(11):2365-70, 2006
  • Elias D, Avron A, Tamir M, Raz I: DiaPep277 preserves endogenous insulin production by immunomodulation in type 1 diabetes. Ann NY Acad Sci 1079:340-4, 2006
  • Cernea S, Raz I: Noninjectable methods of insulin administration. Timely Top Med Cardiovasc Dis10;E29, 2006 Review
  • Raz I, Avron A, Tamir M, Metzger M, Symer L, Eldor R, Cohen IR, Elias D. Treatment of new-onset type 1 diabetes with peptide DiaPep277 is safe and associated with preserved beta-cell function: extension of a randomized, double-blind, phase II trial. Diabetes Metab Res Rev 23:292-298, 2007
  • Khamaisi M, Regev E, Yarom N, Avni B, Leitersdorf E, Raz I, Elad S: Possible association between diabetes and bisphosphonate-realted jaw osteoneonecrosis. J Clin Endocrinol Metab 92(3):1172-5, 2007
  • Yagil C, Barkalifa R, Sapojnikov M, Wechsler A, Ben-Dor D, Weksler-Zangen S, Kaiser N, Raz I, Yagil Y: Metabolic and genomic dissection of diabetes in the Cohen rat. Physiol Genomics April 24;29(2):181-192, 2007
  • Ryden L, Stankl E, Barnik M, Vanden Berghe G, Betteridge J, de Boer MJ, Cosentino F, Honsson B, Laakso M, Malmberg K, Priori S, Ostergren J, Tuomilehto J, Thrainsdottir I, Vanhorebeek I, Stramba-Badiale M, Lindgren P, Qiao Q, Priori SG, Blanc JJ, Budaj A, Camm J, Dean V, Deckers J, Dickstein K, Lekakis J, McGregro K, Metra M, Morais J, Osterspey A, Tamargo J, Zamorano JL, Deckers JW, Bertrand M, Chabonnel B, Erdmann E, Ferrannini E, Flyvbjerg A, Gohlke H, Juanatey JR, Graham I, Monteiro Pf, Parhofer K, Pyorala K, Raz I, Schernthaner G, Volpe M, Wood D: Task Force on Diabetes and Cardiovascular Diseases  of the European Society of Cardiology (ESC); European Association for the Study of Diabetes. Guidelines on diabetes, pre-diabetes and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD) Eur Heart J 28(1):88-136, 2007
  • Dankner R, Abdul-Ghani MA, Gerber Y, Chetrit A, Wainstein J, Raz I: Predicting the 20-year diabetes incidence rate. Diabetes Metab Res Rev Oct:23(7):551-558, 2007
  • Weiss R, Yegorchikov Y, Shusterman A, Raz I: Noninvasive continuous glucose monitoring using photoacoustic technology-results from the first 62 subjects. Diabets Technol Ther 9(1):68-74,  2007
  • Raz I: Sitagliptin: a viewpopint by Itamar Raz. Drugs 67(4):598-599, 2007
  • Khamaisi M, Sondergaard M, Segev Y, Dagnaes-Hansen F, Jensen TG, Landau D, Raz I, Flyvbjerg A: Differential effects on kidney and liver growth of a non-viral hGh-expression vector in hypophysectomized mice. Growth Horm IGF Res Aug;17(4):279-287, 2007
  • Elinav H, Wolf Z, Szalat A, Bdolah-Abram T, Glaser B, Raz I, Leibowitz G: In-hospital treatment of hyperglycemia: effects of intensified subcutaneous insulin treatment. Curr Med Res Opin Apr;23(4):757-765. 2007
  • Weiss R, Raz I: Diabetic ketoacidosis--beware of cerebral edema! Harefuah 146(12):939, 99, 2007 (Hebrew)
  • Raz I, Eldor R: New treatments for diabetes. N  Engl J Med May 24; 356(21):2222, author reply 2222-2223, 2007
  • Bakris Gl, Ruilope L, Locatelli F, Ptaszynska A, Pieske B, de Champlain J, Weber MA, Raz I: Treatment of microalbuminuria in hypertensive subjects with elevated cardiovascular risk: results of the IMPROVE trial. Kidney Int Oct;72(7): 879-885, 2007
  • Weiss L, Zeira M, Reich S, Slavin S, Raz I, Mechoulam R, Gallily R: Cannabidiol arrests onset of autoimmune diabetes in NOD mice. NeuropharmacologyJan;54(1):244-249, 2008
  • Shai I, Wainstein J, Harman-Boehm I, Raz I, Fraser D, Rudich A, Stampfer MJ: Glycemic effects of moderate alcohol intake among patients with type 2 diabetes: a multicenter, randomized, clinical intervention trial. Diabetes Care Dec;30(12):3011-3016, 2007
  • Naor D, Nedvetzki S, Walmasley M, Yayon A, Turley EA, Golan I, Caspi D, Sebban LE, Zick Y, Garin T, Karussis D, Assaya-Asherie N, Raz I, Weiss L, Slavin S, Golan I: CD44 involvement in autoimmune inflammations: the lesson to be learned from CD44-targeting by antibody or from knockout mice. Ann NY Acad Sci Sep;1110:233-247, 2007
  • Weiss R, Niecestro R, Raz I: The role of sulodexide in the treatment of diabetic nephropathy. Drugs 67(18):2681-2696, 2007
  • Heerspink HL, Greene T, Lewis JB, Raz I, Rohde RD, Hunsicker LG, Schwartz SL, Aronoff S, Katz MA, Eisner GM, Mersey JH, Wiegmann TB: for the Collaborative Study Group. Effects of sulodexide in patients with type 2 diabetes and persistent albuminuria. Nephrol Dial Transplant Jun;23(6):1946-54, 2008
  • Weksler-Zangen S, Raz I, Lenzen S, Jorns A, Ehrenfeld S, Amir G, Oprescu A, Yagil Y, Yagil C, Zangen DH, Kaiser N: Impaired glucose stimulated insulin secretion is coupled with exocrine pancreatic lesions in the Cohen diabetic rat. Diabetes Feb;57(2):279-87, 2008
  • Raz I, Chen Y, Wu M, Hussain S, Kaufman KD, Amatruda JM, Langdon RB, Stein PP, Alba M: Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes.
  • Curr Med Res Opin 24(2):537-50, 2008
  • Feder J, Blech I, Ovadia O, Amar S, Wainstein J, Raz I, Dadon S, Arking DE, Glaser B, Mishmar D: Differences in mtDNA haplogroup distribution among 3 Jewish populations alter susceptibility to T2DM complications. BMC Genomics. 29;9(1):198, 2008
  • Khamaisi M, Raz I, Shilo V, Shina A, Rosenberger C, Dahan R, Abassi Z, Meidan R, Lecht S, Heyman SN: Diabetes and radiocontrast media increase endothelin converting enzyme-1 in the kidney. Kidney Int 74(1):91-100, Jul; 2008
  • Davies M, Lavalle-González F, Storms F, Gomis R; AT.LANTUS Study Group: Initiation of insulin glargine therapy in type 2 diabetes subjects suboptimally controlled on oral antidiabetic agents: results from the AT.LANTUS trial.  Diabetes Obes Metab 10(5):387-99, 2008. Epub 2008 Mar 18
  • Bachrach G, Muster Z, Raz I, Chaushu G, Stabholz A, Nussbaum G, Gutner M, Chaushu S: Assessing the levels of immunoglobulins in the saliva of diabetic individuals with periodontitis using checkerboard immunodetection. Oral Dis. Jan;14(1):51-9, 2008
  • de Zeeuw D, Raz I: Albuminuria: a great risk marker, but an underestimated target in diabetes. Diabetes Care 31 Suppl 2:S190-3, 2008. No abstract available.
  • Milicevic Z, Raz I, Beattie SD, Campaigne BN, Sarwat S, Gromniak E, Kowalska I, Galic E, Tan M, Hanefeld M: Natural history of cardiovascular disease in patients with diabetes: role of hyperglycemia. Diabetes Care 31 Suppl 2:S155-60, 2008
  • Raz I, Weiss R: The Controversies in Obesity, Diabetes and Hypertension (CODHy) meeting: what is it all about?  Diabetes Care 31 Suppl 2:S111-2, 2008
  • Sjolie Ak, Klein R, Porta M, Orchard T, Fuller J, Parving Hh, Bilous R, Chaturvedi N; DIRECT Programme Study Group. Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT_Protect 2): a randomized placebo-controlled trial. Lancet 372(9647): 1385-1393, Oct 18; 2008
  • Chaturvedi N, Porta M, Klein R, Orchard T, Fuller J, Parving HH, Bilous R, Sjolie AK; DIRECT Programme Study Group. Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomized, placebo-controlled trials. Lancet  372(9647):1394-1402, Oct 18;2008
  • Feder J, Blech I, Ovadia O, Amar S, Wainstein J, Raz I, Dadon S, Arking DE, Glaser B,l Mishmar D. Differences in mtDNA haplogroup distribution among 3 Jewish populations alter susceptibility to T2DM complications. BMC Genomics 9:198, 2008
  • Auryan S, Itamar R. Gender-specific care of diabetes mellitus: particular considerations in the management of diabetic women. Diabets Obes Metab  10(12):1135-1156, Dec; 2008.
  • Kjamaisi M, Dahan R, Hamed S, Abassi Z, Heyman SN, Raz I. Role of protein kinase C in the expression of endothelin converting enzyme-1. Endocrinology 150(3):1440-1449, Mar; 2009.
  • Zigmond E, Zangen SW, Pappo O, Sklair-Levy M, Lalazar G, Zolotaryova L, Raz I, Ilan Y. Beta-glycosphingolipids improve glucose intolerance and hepatic steatosis of the Cohen diabetic rat. Am J Physiol Endocrinol Metab 296(1) E72-78, Jan; 2009.
  • Keidar A, Abu Abeid S, Lieberman G, Bachrach R, Zacharovitch D, Raz I. Surgical treatment of morbid obesity. Harefuah 147(11):879-884, 940-941, 2008 (Hebrew)
  • Raz I, Wilson PW, Strojek K, Kowalska I, Bozikov V, Gitt AK, Jermendy G, Campaigne BN, Kerr L, Milievic Z, Jacober SJ. Effects of prandial versus fasting glycemia on cardiovascular outcomes in type 2 diabetes: the HEART2D trial. Diabetes Care  32(3):381-386, Mar; 2009
  • Eldor R, Kassem S, Raz I. Immune modulation in type 1 diabetes mellitus using DiaPep277: a short review and update of recent clinical trial results. Diabetes Metab Res Rev. May;25(4):316-20, 2009
  • Eldor R, Raz I. The individualized target HbA1c: A new method for improving macrovascular risk and glycemia without hypoglycemia and weight gain. Rev Diabet Stud. 2009 Spring; 6(1)6-12. [Epub 2009 May 10]
  • Raz I, Weiss R, Yegorchikov Y, Bitton G, Nagar R, Pesach B. Effect of a local heating device on insulin and glucose pharmacokinetic profiles I an open-label, randomized, two-period, one-way crossover study in patients with type 1 diabetes using continuous subcutaneous insulin infusion. Clin Ther May;31(5):980-987, 2009
  • Unnikrishnan AG, Tibaldi J, Hadley-Brown M, Krentz AJ, Ligthelm R, Damci T, Gumprect J, Gero L, Mu Y, Raz I. Practical guidance on intensification of insulin therapy with BIAsp30: a consensus statement. Int J Clin Pract  Nov; 63(11):1571-1577, 2009 [Epub 2009 Sep 19].
  • Cernea S, Raz I, Herold KC, Hirshberg B, Roep BO, Schatz DA, Fleming GA, Pozzilli P, Little R, Schloot NC, Leslie RD, Skyler JS, Palmer JP. Challenges in developing endpoints for type1 diabetes intervention studies. Diabetes Metab Res Rev Nov 25(80): 694-704, 2009
  • Dankner R, Chetrit A, Shanik MH, Raz I, Roth J. Basal-state hyperinsulinemia in healthy normoglycemic adults in predictive of type 2 diabetes over a 24-year follow-up: a preliminary report. Diabetes Care Aug;32(8):1464-1466, 2009
  • Chacra AR, Tan GH, Apanovitch A, Ravichandran S, List J, Chen R; CV181-040 Investigators. Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial. Int J Clin Pract  Sep;63(9):1395-406, 2009
  • Kassem SA, Raz I. Is there evidence that oral hypoglycemic agents reduce cardiovascular morbidity or mortality? No. Diabetes Care Nov 32(Suppl 2) S337-S341, 2009
  • Eldor R, Raz I. American Diabetes Association indications for statins in diabetes: is there evidence? Diabetes Care Nov 32(Suppl 2) S384-S391, 2009
  • Raz, I. Introduction to the Second World Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension (CODHy): dilemmas in clinical practice. Diabetes Care Nov 32 (Suppl 2):S149-50, 2009
  • Nahmias A, Tamir O, Raz I, Wainstein J. In anticipation of patient participation. Isr Med Assoc J. 11(12):751-2, 2009
  • Raz I. Relationship between blood glucose control and improved cardiovascular outcome after stent implantation in diabetic patients. Cardiology 116(1)48-50, 2010
  • Pozzilli P, Leslie RD, Chan J, De Fronzo R, Monnier L, Raz I, Del Prato S. The A1C  and ABCD of glycaemia management in type 2 diabetes: a physician's personalized approach. Diabetes Metab Res Rev 26(4):239-44, 2010
  • Mizrahi M, Lalazar G, Adar T, Raz I, Ilan Y. Assessment of insulin resistance by a 13C glucose breath test: a new tool for early diagnosis and follow-up of high-risk patients. Nutr J 9:25, 2010
  • Keidar A, Schweiger C, Raz I. New insight into old disease: potential treatment of type 2 diabetes mellitus by bariatric surgery. Harefuah 149(2):95-8, 2010 (Hebrew)
  • Dankner R, Chetrit A, Murad H, Sela BA Frystyk J, Raz I, Flyvbjerg A. Serum adiponecti is associated with homocysteine in elderly men and women, and with 5, 10-methylenetetrahydrofolate reductase (MTHFR) in a sex-dependent manner. Metabolism  Dec;59(12):1767-74, 2010
  • Glandt M, Raz I. Pharmacotherapy: ACCORD Blood pressure and ACCORD lipid: How low can we go? Nat Rev Endocrinol 6(9):483-4, 2010
  • Stenlof K, Raz I, Neutel J, Ravichandran S, Berglind N, Chen R. Saxagliptin and metformin XR combination therapy provides glycemic control over 24 hours in patients with T2DM inadequately controlled with metformin. Curr Med Res Opin. Oct;26(10):2355-63, 2010
  • Cernea S, Dobreanu M, Raz I. Prevention of type 1 diabetes: today and tomorrow. Diabetes Metab Res Rev. Nov;26(8):602-5, 2010
  • Leibowitz G, Raizman E, Brezis M, Glaser B, Raz I, Shapira O. Effects of moderate intensity glycemic control after cardiac surgery. Ann Thorac Surg. Dec;90(6):1825-32, 2010
  • Levin-laina N, Laina A, Raz I. The emerging role of NO and IGF-1 in early renal hypertrophy in STZ-induced diabetic rats. Diabetes Metab Res Rev Mar;27(3):235-243. doi: 10.1002/dmrr.1172, 2011
  • Prota M, Hainer JW, Jansson SO, Malm A, Bilous R, Chaturvedi N, Fuller JH, Klein R, Orchard T, Parving HH, Sjolie AK;DIRECT Study Group. Exposure to candesartan during the first trimester of pregnancy in type 1 diabetes: experience from the placebo-controlled diabetic retinopathy candesartan trials. Diabetologia Jun;54(6):1298-1303. Epub 2011 Jan 12
  • Glandt M, Raz I. Present and future: pharmacologic treatment of obesity. J Obes. 2011:636181. Epub 2011 Feb 8
  • Glandt M, Raz I. Analysis: accuracy performance of the Medtronic NexSensor for 6 days in an inpatient setting using abdomen and buttocks insertion sites. J Diabetes Sci Technol Mar 1;5(2):365-367, 2011
  • Hirshberg B, Raz I. Impact of the U.S. Food and Drug Administration cardiovascular assessment requirements on the development of novel antidiabetes drugs. Diabetes Care May;34 Suppl 2:S101-106, 2011
  • Cernea S, Raz I. Therapy in the early stage: incretins. Diabetes Care 34 Suppl 2:S264-271, 2011
  • Raz I, Del Prato S. Introduction to the Third World Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension (CODHy): outcome studies versus clinical experience in the treatment of diabetes. Diabetes Care 34 Suppl 2:S99-100, 2011
  • Schroeder JE, Liebergall M, Raz I, Egleston R, Sussan GB, Peyser A, Eldor R.Four by four; Simple glycemic control in an orthopedic surgery ward - a randomized prospective study of a four step intervention process. Diabetes Metab Res Rev. 2011 May 17. doi:  10.1002/dmrr.1217. [Epub ahead of print]
  • Raz I, Ceriello A, Wilson PW, Battioui C, Su EW, Kerr L, Jones CA, Milicevic Z, Jacober SJ. Post Hoc Subgroup Analysis of the HEART2D Trial Demonstrates Lower Cardiovascular Risk in Older Patients Targeting Postprandial Versus Fasting/Premeal Glycemia. Diabetes Care Jul;34(7):1511-3. Epub 2011 May 18. 2011
  • Lewis EJ, Greene T, Spitalewiz S, Blumenthal S, Berl T, Hunsicker LG, Pohl MA, Rohde RD, Raz I, Yerushalmy Y, Yagil Y, Herskovitz T, Packham DK, Lewis JB; for the Collaborative Study Group. Pyridorin in Type 2 Diabetic Nephropathy, J Am Soc Nephrol. 2011 Oct 27. [Epub ahead of print]
  • Packham DK, Wolfe R, Reutens AT, Berl T, Heerspink HL, Rohde R, Ivory S, Lewis J, Raz I, Wiegmann TB, Chan JC, de Zeeuw D, Lewis EJ, Atkins RC; for the Collaborative Study Group. Sulodexide Fails to Demonstrate Renoprotection in Overt Type 2 Diabetic Nephropathy. J Am Soc Nephrol. 2011 Oct 27. [Epub ahead of print]
  • Brito M, Ligthelm RJ, Boemi M, Kumar A, Raz I, Koblik T, Gao Y, Christiansen JS. Intensifying existing premix therapy (BIAsp 30) with BIAsp 50 and BIAsp 70:A consensus statement. Indian J Endocrinol Metab. 2011 Jul;15(3):152-60
  • Lewis EJ, Lewis JB, Greene T, Hunsicker LG, Berl T, Pohl MA, de Zeeuw D, Heerspink HL, Rohde RD, Atkins RC, Reutens AT, Packham DK, Raz I; Collaborative Study Group. Sulodexide for kidney protection in type 2 diabetes patients with microalbuminuria: a randomized controlled trial. Am J Kidney Dis. 2011 Nov;58(5):729-36. Epub 2011 Aug 26.
  • Lewis EJ, Greene T, Spitalewiz S, Blumenthal S, Berl T, Hunsicker LG, Pohl MA, Rohde RD, Raz I, Yerushalmy Y, Yagil Y, Herskovits T, Atkins RC, Reutens AT, Packham DK, Lewis JB; for the Collaborative Study Group. Pyrodin in Type 2 Diabetic Neuropathy. J Am Soc Nephrol. 2011 Nov 10. [Epub ahead of print]
  • Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, Ohman P, Price DL, Chen R, Udell J, Raz I.  The design and rationale of the Saxagliptin Assessment of Vascular Outcomes Recorded in patients with diabetes mellitus-Thrombolysis in Myocardial Infarction (SAVOR-TIMI) 53 Study. Am Heart J. 2011 Nov;162(5):818-825.e6.
  • Raz I, Eldor R. Rational therapy for Diabetes: Early recognition of adverse effects and avoidance of disruptive false alarms. Diabetes Metab Res Rev. 2011 Dec 15.doi:10.1002/dmrr.2265. [Epub ahead of print]
  • Weksler-Zangen S, Mizrahi T, Raz I, Mirsky N. Glucose tolerance factor extracted from yeast: oral insulin-mimetic and insulin-potentiating agent: in vivo and in vitro studies. Br J Nutr. 2011 Dec 15:1-8. [Epub ahead of print]
  • Raz I, Gallwitz B. The continuing need for drug development and clinical trials in type 2 diabetes and its complications: Introduction to the RDS Special Issue. Rev Diabet Stud. 2011 Fall;8(3):288-92. Epub 2011 Nov 10
  • Raz I, Fonseca V, Kipnes M, Durrwell L, Hoekstra J,Boldrin M, Balena R. Efficacy and safety of taspoglutide monotherapy in drug-naïve type 2 diabetic patients after 24 weeks of treatment: results of a randomized, double-blind, placebo-controlled phase 3 study (T-emerge 1). Diabetes Care. 2012 Mar:35(3):485-487
  • Udell JA, Scirica BM, Braunwald E, Raz I, Steg PG, Davidson J, Hirshberg B, Bhatt KL. Statin and aspirin therapy for the prevention of cardiovascular events in patients with type 2 diabetes mellitus. Clin Cardio.2012 Jul 3.doi: 10.1002/clc.22032. [Epub ahead of print]
  • Raz I, Amiel SA, Alberti G, Shehadeh N, Del Prato S, Zimmet P, Cefalu WT. Global call for free academic movement for international dialogue. Diabetes Care. 2012 35(8):1631-2
  • Dankner R, Chetrit A, Shanik MH, Raz I, Roth J. Basal state hyperinsulinemia in healthy normoglycemic adults heralds dysglycemia after more than two decades of follow up. Diabetes Metab Res Rev. 2012 Oct;28(7):618-24
  • Tamir O, Wainstein J, Raz I, Shemer J, Heymann A. Quality of life and patient-perceived difficulties in the treatment of type 2 diabetes. Rev Diabet Stud.2012 Spring;9(1):46-54
  • Raz I. Exogenous hyperinsulinemia and atherosclerosis in type 1 diabetic patients. J Diabetes Complications.2012 Nov 11 doi:pii: S1056-8727(12)00283-8. 10.1016/j.jdiacomp.2012.10.003. [Epub ahead of print]
  • Eldor R, Raz I. Diabetes therapy-focus on Asia: second-line therapy debate: insulin/secretagogues. Diabetes Metab Res Rev.2012 Dec;28 Suppl 2:85-9.doi: 10.1002/dmrr.2358
  • Mosenzon O, Raz I. Potential cardiovascular effects of dipeptidyl
  • peptidase-4 inhibitors in patients with type 2diabetes: current evidence and ongoing trials. European Heart Journal Supplements 2012 14 (Supplement B), B22–B29 doi:10.1093/eurheartj/sus003
  • Meneghini L, Atkin SL, Gough SC, Raz I, Blonde L, Shestakova M, Bain S, Johansen T, Begrup K, Birkeland KI;NN1250-3668 (BEGIN FLEX) Trial Investigators. The efficacy and safety of insulin degludec given in variable once-daily dosing intervals compared with insulin glargine and insulin degludec dosed at the same time daily: a 26-week, randomized, open-label, parallel-group, treat-to-target trial in individuals with type 2 diabetes. Diabetes Care. 2013 Apr;36(4):858-64.doi.2337/dc12-1668. Epub 2013 Jan 22
  • Livshits L, Srulevich A, Raz I, Cahn A, Barshtein G, Yedgar S, Eldor R. Effect of short-term hyperglycemia on protein kinase C alpha activation I human erythrocytes. Rev Diabet Stud. 2012 Summer-Fall;9(2-3):94-103.doi: 10.1900/RDS.2012.9.94. Epub 2012 Nov 15
  • Dickman R, Dislov J, Boaz M, Ron Y, Beniashvili Z, Raz I, Baigel I, Niv Y, Wainstein J. Prevalence of symptoms suggestive of gastroparesis in a cohort of patients with diabetes mellitus. J Diabetes Complications. 2013 Mar 15:doi:pii:S1056-8727(13)00050-0.10.1016/j.jdiacomp.2013.02.004. [Epub ahead of print]
  • Weksler-Zangen S, Jorns A, Tarsi-Chen L, Vernea F, Aharon-Hananel G, Saada A, Lenzen S, Raz I. Dietary copper supplementation restores beta-cell function of Cohen diabetic rats: a link between mitochondrial function and glucose-stimulated insulin secretion. Am J Physiol Endocrino Metab. 2013 May;304(10)E1023-34.doi: 10.1152/ajpendo.00036.2013. Epub 2013 Mar 19.
  • Mosenzon O, Raz I, Scirica BM, Hirshberg B, Stahre CI, Steg PG, Davidson J, Ohman P, Price DL, Frederich B, Udell JA, Braunwald E, Bhatt DOL. Baseline characteristics of outpatient population in the Saxagliptin Assessment of Vascular Outcomes Recorded in patients with diabetes mellitus (SAVOR) – TIMI 53 Trila. Diabetes Metab Res Rev. 2013 Apr 6. Doi: 10.1002/dmrr.2413. Epub ahead of print
  • Cahn A, Raz I. Emerging gliptins for type 2 diabetes. Expert Opin Emerg Drugs. 2013 Jun;18(2):245-58
  • Raz I, Riddle MC, Rosenstock J, Buse JB, Inzucchi SE, Home PD, Del Prato S, Ferrannini E, Chan JC, Leiter LA, Leroith D, DeFronzo R, Cefalu WT. Personalized management of hyperglycemia in type 2 diabetes: reflections from a Diabetes Care Editors' Expert Forum. Diabetes Care. 2013 Jun;36(6):1779-88
  • Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, Ohman P, Frederich R, Wiviott SD, Hoffman EB, Cavender MA, Udell JA, Desai NR, Mosenzon O, McGuire DK, Ray KK, Leiter LA, Raz I; the SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus. N Engl J Med. 2013 Oct 3;369(14)1317-26
  • Mosenzon O, Raz I. Intensification of Insulin Therapy for Type 2 Diabetic Patients in Primary Care: Basal-Bolus Regimen Versus Premix Insulin Analogs: When and for whom? Diabetes Care. 2013 Aug;36 Suppl 2:S212-8
  • Raz I. Guideline approach to therapy in patients with newly diagnosed type 2 diabetes. Diabetes Care. 2013 Aug;36 Suppl 2:S139-44
  • Del Prato S, Raz I. Introduction to the 4th World Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension (CODHy). Diabetes Care. 2013 Aug;36 Suppl 2:S111-2
  • Raz I, Mosenzon O. Early insulinization to prevent diabetes progression. Diabetes Care. 2013 Aug;36 Suppl 2:S190-7. doi: 10.2337/dcS13-201
  • Smink PA, Miao Y, Eijkemans MJ, Bakker SJ, Raz I, Parving HH, Hoekman J, Grobbee DE, de Zeeuw D, Heerspink HJ. The importance of short-term off-target effects in estimating the long-term renal and cardiovascular protection of Angiotensin Receptor Blockers. Clin Pharmacol Ther. 2014 Feb;95(2):208-15. doi: 10.1038/clpt.2013.191.
  • Weksler-Zangen S, Aharon-Hananel G, Mantzur C, Aouizera T, Gurgul-Convey E, Raz I, Saada A. Interleukin-1β hampers glucose stimulated insulin secretion in Cohen diabetic rat islets through mitochondrial cytochrome c oxidase inhibition by nitric-oxide. Am J Physiol Endocrinol Metab. 2014 Jan 14. [Epub ahead of print]
  • Pozzilli P, Raz I, Peled D, Elias D, Avron A, Tamir M, Eren R, Dagan S, Cohen IR. Evaluation of Long-Term Treatment Effect in a Type 1 Diabetes Intervention Trial: Differences After Stimulation With Glucagon or a Mixed Meal. Diabetes Care. 2014 Jan 9. [Epub ahead of print]PMID: 24408401 [PubMed - as supplied by publisher]
  • Pfützner A, Hermanns N, Funke K, Forst T, Behnke T, Bitton G, Nagar R, Raz I, Haak T. The Barmer study: impact of standardized warming of the injection site to enhance insulin absorption and reduce prandial insulin requirements and hypoglycemia in obese patients with diabetes mellitus. Curr Med Res Opin. 2014 Jan 17. [Epub ahead of print]PMID: 24392996 [PubMed - as supplied by publisher]
  • Landau Z, Klonoff D, Nayberg I, Feldman D, Levit SB, Lender D, Mosenzon O, Raz I, Wainstaein J. Improved pharmacokinetic and pharmacodynamic profile of insulin analogs using InsuPatch, a local heating device. Diabetes Metab Res Rev. 2014 Mar 10. Doi: 10.1002/dmrr.2536. [Epub ahead of print]
  • Raz I, Ziegler AG, Linn T, Schernthaner G, Bonnici F, Distiller LA, Giordano C, Giorgino F, de Vries L, Mauricio D, Prochazka V, Wainstein J, Elias D, Avron A, Tamir M, Eren R, Peled D, Dagan S, Cohen IR, Pozzilli P; DIA-AID 1 Writing Group. Treatment of recent-onset type 1 diabetic patients with DiaPep277: results of a double-blind placebo-controlled randomized Phase 3 trial. Diabetes Care.2014 May;37(5):1392-400
  • Home P, Riddle M, Cefalu WT, Bailey CJ, Bretzel RG, Del Prato S, Leroith D, Schernthaner G, van Gaal L, Raz I. Insulin therapy in people with type 2 diabetes: opportunities and challenges. Diabetes Care. 2014 June;37(6):1499-508
  • Raz I, Bhatt DL, Hirshberg B, Mosenzon O, Scirica BM, Umez-Eronini A, Im K, Stahre C, Buskila A, Iqbal N, Greenberger N, Lerch MM. Incidence of pancreatitis and pancreatic cancer in a randomized controlled multicenter trial (SAVOR-TIMI 53) of the dipeptidyl peptidase-4 (DPP-4) inhibitor saxagliptin. Diabetes Care. 2014 Sep;37(9):2435-41
  • Cefalu WT, Buse JB, Del Prato S, Home PD, LeRoith D, Nauck MA, Raz I, Rosenstock J, Riddle MC. Beyond metformin: safety considerations in the decision-making process for selecting a second medication for type 2 diabetes management: reflections from a diabetes care editors' expert forum. Diabetes Care. 2014 Sep;37(9):2647-59
  • Scirica BM, Braunwald E, Raz I, Cavender MA, Morrow DA, Jarolim P, Udell JA, Mosenson O, Im K, Umez-Eronini AA, Pollack PS, Hirshberg B, Frederich R, Lewis BS, McGuire DK, Davidson J, Steg PG, Bhatt DL; for the SAVOR-TIMI 53 Steering Committee and Investigators. Heart failure, saxagliptin and diabetes mellitus: Observations from the SAVOR-TIMI 53 randomized trial. Circulation. 2014.pii:CIRCULATIONAHA.114.010389. [Epub ahead of print]
  • Zigmond E, Tayer-Shifman O, Lalazar G, Ben Ya'acov A, Weksler-Zangen S, Shasha D, Sklair-Levy M, Zolotarov L, Shalev Z, Kalman R, Ziv E, Raz I, Ilan Y. β-glycosphingolipids ameliorated non-alcoholic steatohepatitis in the Psammomys obesus model. J Inflamm Res. 2014 Oct 8;7:151-8.
  • Home P, Riddle M, Cefalu WT, Bailey CJ, Bretzel RG, Del Prato S, Leroith D, Schernthaner G, van Gaal L, Raz I. Response to comment on home et Al. Insulin therapy in people with type 2 diabetes: opportunities and challenges? Diabetes care 2014;37:1499-1508. Diabetes Care. 2014 Nov;37(11):e247. doi: 10.2337/dc14-1790

Editor-Books

Diabetes in the Third Millennium, Published by the Israel Diabetes Association, Tel-   Aviv, 2002

  • M Dunitz - Diabetes: From Research to Diagnosis and Treatment. Edited by Raz I, Skyler J and Shafrir E.  Published by M. Dunitz, Taylor and Francis Associates U.K. 2002.
  • Chapters in Books:

    • Michaeli JU, Lugassy G, Raz I,  Polliack A. Chronic lymphocytic leukemia. Chapter 17. A. Polliack, and D. Catovsky, editors, Harwood Academic Publishers. London - New York, pp. 231-248,  1988
    • Flyvbjerg A,  Landau D,  Klien W,  Bondy C,  Chine E,  Raz I, Phillip M,  Leroith D. The role of insulin-like growth factors (IGFS) and IGF binding protein in diabetic nephropathy. Proceedings of the 15th International Diabetes Federation. 1995.
    • Raz I, Wexler ID. Extra-renal complications of the type 2 diabetic patient with diabetic nephropathy. In: Nephropathy in Type 2 Diabetes. Ritz, E., Flisher, D. (eds.) London: Oxford University. Publisher Oxford New York Oxford University Press 1999. 
    • Guest Editor: Diabetes-inevitable or preventable?  Diabetes-Obesity-Metabolism 3: (supl 1)1-    43, 2001.
    • Khamaisi M, Symmer L, Raz I. Thiazolidinediones in cardiovascular risk in type 2 diabetes mellitus. In: Cardiovascular risk in type 2 diabetes: assessment and control. Edited by Nicolae Hancu, Springer-Verlag GmBH, New York ,pp. 193-203, 2002
    • Khamaisi M, Wexler I, Raz I. Cardiovascular disease in type 2 diabetes. In : Diabetes :From Research to Diagnosis and Treatment. Edited by I. Raz, E. Shafrir published by M. Dunitz, Taylor and Francis Associates U.K 2002.

    Itamar Raz

    Professor

     

    • : (972) 2-6777535, 2-6778021

    • DEPARTMENT

      Diabetes Unit,
      Hadassah Hebrew University Hospital


    • COUNTRY ISRAEL